Patients with multiple sclerosis found that their symptoms did not worsen with intake of tolebrutinib, in the GEMINI 1 and 2 studies.

But tolebrutinib showed something novel at ECTRIMS. In the phase III HERCULES trial, tolebrutinib slowed confirmed disability ...

Sanofi has released phase 3 data from the LUNA 3 trial of rilzabrutinib that should spark some buyer’s delight. | Sanofi has released phase 3 data from the LUNA 3 trial of rilzabrutinib that should ...

Last year, the FDA placed similar partial clinical holds on Sanofi’s late-stage candidate tolebrutinib – holding up a programme that was a key part of the drugmaker’s $3.7 billion buyout of ...

Circle to Search is coming to compatible phones with OxygenOS 15 The update also adds new boot animation, icons, and shelf card choices OxygenOS 15 introduces Gemini-powered AI Notes ...

The company is also working toward FDA filings for tolebrutinib in secondary progressive multiple sclerosis and Dupixent for chronic spontaneous urticaria. On Friday, Sanofi was revealed as a new ...

A screenshot of the ABC News-hosted presidential debate between Kamala Harris and Donald Trump in September 2024. Picture: Youtube screenshot of Wall Street Journal debate stream Half of the world ...

Phase 3 trial results Tolebrutinib (Sanofi) Bruton tyrosine kinase inhibitor Treatment of non-relapsing secondary progressive multiple sclerosis. Phase 3 trial results Depemokimab (GSK) Ultra-long ...

Findings showed the study met its primary endpoint demonstrating a reduction in disability accumulation with tolebrutinib compared with placebo. Tolebrutinib was found to delay disability progression ...

But three — tolebrutinib, fenebrutinib, and remibrutinib — are now in late-stage trials. The race is on as several drugmakers get closer to the finish line in developing the first Bruton tyrosine ...

A positive result for Bruton’s tyrosine kinase inhibitor after the drug had been put on partial clinical hold due to concerns about liver toxicity.

One highlight that could directly affect patient care was the trial results for tolebrutinib. Although phase 3 trials did not meet their primary endpoint in relapsing-remitting MS, the treatment ...